Evidence map›Paper›PMID 40654997›Full record

ArticlebioRxiv : the preprint server for biology2025

Scouring the human Hsp70 network uncovers diverse chaperone safeguards buffering TDP-43 toxicity.

Edward M Barbieri, Miriam Linsenmeier, Katherine R Whiteman, Yan Cheng, Sylvanne Braganza, Katie E Copley, Paola Miranda-Castrodad, Brennen Lewis, Kevin Villafañe, Defne A Amado and 2 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Edward M BarbieriDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. U.S.A.
Miriam LinsenmeierDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. U.S.A.
Katherine R WhitemanRaymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104. U.S.A.
Yan ChengDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. U.S.A.
Sylvanne BraganzaDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. U.S.A.
Katie E CopleyDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. U.S.A.
Paola Miranda-CastrodadDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. U.S.A.
Brennen LewisDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. U.S.A.
Kevin VillafañeDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. U.S.A.
Defne A AmadoRaymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104. U.S.A.ORCID 0000-0001-6202-3900
Beverly L DavidsonRaymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104. U.S.A.
James ShorterDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. U.S.A.ORCID 0000-0001-5269-8533

Funding

Defining the mechanistic basis of a prion disaggregaseR01GM099836 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI SHORTER, JAMES · 2013 to 2024
$3.9M
Structural biology and molecular biophysics training programT32GM132039 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Ben E. Black, Elizabeth Rhoades · 2019 to 2026
$3.3M
Viral-based Therapeutic Approaches for Reversal of ALS PathologyK08NS114106 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI AMADO, DEFNE AUDREY · 2020 to 2024
$1.1M
Programming human protein disaggregases against FTDR21AG065854 · NIA · UNIVERSITY OF PENNSYLVANIA · PI SHORTER, JAMES · 2020 to 2020
$446k
Synthetic Reconstruction of Human Chaperone Networks in Yeast Models of NeurodegenerationK99AG075242 · NIA · UNIVERSITY OF PENNSYLVANIA · PI BARBIERI, EDWARD MATTHEW · 2023 to 2024
$231k
Programming Human Chaperone Systems Against Neurodegenerative DiseaseF32NS108598 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI BARBIERI, EDWARD MATTHEW · 2019 to 2021
$193k
Developing RNA therapeutics for TDP-43 proteinopathy in ALS/FTDF31NS129101 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI COPLEY, KATIE ELIZABETH · 2022 to 2024
$131k
NIA NIH HHS K99 AG075242NIA NIH HHS R21 AG065854NIGMS NIH HHS R01 GM099836NIGMS NIH HHS T32 GM132039NINDS NIH HHS F31 NS129101NINDS NIH HHS F32 NS108598NINDS NIH HHS K08 NS114106
6 · The paper itself

Abstract

Cytoplasmic aggregation and concomitant dysfunction of the prion-like, RNA-binding protein TDP-43 underpin several fatal neurodegenerative diseases, including amyotrophic lateral sclerosis. To elucidate endogenous defenses, we systematically scoured the entire human Hsp70 network for buffers of TDP-43 toxicity. We identify 30 J-domain proteins (2 DNAJAs, 10 DNAJBs, 18 DNAJCs), 6 Hsp70s, and 5 nucleotide-exchange factors that mitigate TDP-43 toxicity. Specific chaperones reduce TDP-43 aggregate burden and detoxify diverse synthetic or disease-linked TDP-43 variants. Sequence-activity mapping unveiled unexpected, modular mechanisms of chaperone-mediated protection. Typically, DNAJBs collaborate with Hsp70 to suppress TDP-43 toxicity, whereas DNAJCs act independently. In human cells, specific chaperones increase TDP-43 solubility and enhance viability under proteotoxic stress. Strikingly, spliceosome-associated DNAJC8 and DNAJC17 retain TDP-43 in the nucleus and promote liquid-phase behavior. Thus, we disambiguate a diverse chaperone arsenal embedded in the human proteostasis network that counters TDP-43 toxicity and illuminate mechanistic gateways for therapeutic intervention in TDP-43 proteinopathies.

Identifiers

PMID40654997
PMCPMC12248113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.